David Westenberg
Stock Analyst at Piper Sandler
(4.62)
# 283
Out of 5,146 analysts
197
Total ratings
58.56%
Success rate
22.76%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WGS GeneDx Holdings | Maintains: Overweight | $160 → $130 | $77.85 | +66.99% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Overweight | $120 → $130 | $94.62 | +37.39% | 11 | Feb 24, 2026 | |
| NEO NeoGenomics | Maintains: Overweight | $12 → $13 | $9.84 | +32.11% | 11 | Feb 24, 2026 | |
| LH Labcorp Holdings | Maintains: Neutral | $270 → $300 | $288.21 | +4.09% | 5 | Feb 24, 2026 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $775 → $750 | $659.63 | +13.70% | 12 | Feb 9, 2026 | |
| ILMN Illumina | Maintains: Overweight | $195 → $170 | $134.29 | +26.59% | 17 | Feb 9, 2026 | |
| ELAN Elanco Animal Health | Upgrades: Overweight | $24 → $30 | $26.31 | +14.03% | 11 | Jan 22, 2026 | |
| ZTS Zoetis | Downgrades: Neutral | $190 → $135 | $132.18 | +2.13% | 16 | Jan 22, 2026 | |
| NEOG Neogen | Reiterates: Neutral | $6.5 → $10 | $11.29 | -11.43% | 14 | Jan 12, 2026 | |
| BLLN BillionToOne | Initiates: Overweight | $150 | $73.97 | +102.78% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $19 | $22.80 | -16.67% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $80 | $52.63 | +52.00% | 6 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $2 | $1.68 | +19.05% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $230 | $207.08 | +11.07% | 17 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $21 → $30 | $15.45 | +94.17% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $80 | $103.05 | -22.37% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7.5 | $4.48 | +67.41% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $190 → $200 | $211.57 | -5.47% | 8 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $16.04 | +24.69% | 15 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $22.44 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $26.54 | - | 1 | Nov 21, 2017 |
GeneDx Holdings
Feb 24, 2026
Maintains: Overweight
Price Target: $160 → $130
Current: $77.85
Upside: +66.99%
Guardant Health
Feb 24, 2026
Maintains: Overweight
Price Target: $120 → $130
Current: $94.62
Upside: +37.39%
NeoGenomics
Feb 24, 2026
Maintains: Overweight
Price Target: $12 → $13
Current: $9.84
Upside: +32.11%
Labcorp Holdings
Feb 24, 2026
Maintains: Neutral
Price Target: $270 → $300
Current: $288.21
Upside: +4.09%
IDEXX Laboratories
Feb 9, 2026
Maintains: Neutral
Price Target: $775 → $750
Current: $659.63
Upside: +13.70%
Illumina
Feb 9, 2026
Maintains: Overweight
Price Target: $195 → $170
Current: $134.29
Upside: +26.59%
Elanco Animal Health
Jan 22, 2026
Upgrades: Overweight
Price Target: $24 → $30
Current: $26.31
Upside: +14.03%
Zoetis
Jan 22, 2026
Downgrades: Neutral
Price Target: $190 → $135
Current: $132.18
Upside: +2.13%
Neogen
Jan 12, 2026
Reiterates: Neutral
Price Target: $6.5 → $10
Current: $11.29
Upside: -11.43%
BillionToOne
Dec 1, 2025
Initiates: Overweight
Price Target: $150
Current: $73.97
Upside: +102.78%
Nov 11, 2025
Maintains: Neutral
Price Target: $15 → $19
Current: $22.80
Upside: -16.67%
Nov 11, 2025
Maintains: Neutral
Price Target: $105 → $80
Current: $52.63
Upside: +52.00%
Nov 11, 2025
Maintains: Neutral
Price Target: $1.5 → $2
Current: $1.68
Upside: +19.05%
Nov 11, 2025
Maintains: Overweight
Price Target: $220 → $230
Current: $207.08
Upside: +11.07%
Nov 11, 2025
Maintains: Neutral
Price Target: $21 → $30
Current: $15.45
Upside: +94.17%
Nov 11, 2025
Maintains: Overweight
Price Target: $70 → $80
Current: $103.05
Upside: -22.37%
Nov 11, 2025
Maintains: Overweight
Price Target: $8 → $7.5
Current: $4.48
Upside: +67.41%
Oct 27, 2025
Maintains: Neutral
Price Target: $190 → $200
Current: $211.57
Upside: -5.47%
Oct 15, 2025
Maintains: Overweight
Price Target: $15 → $20
Current: $16.04
Upside: +24.69%
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $22.44
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $26.54
Upside: -